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Abstract
Background: Dietary polyunsaturated fatty acids (PUFA) are inversely related to coronary heart disease (CHD) in
epidemiological studies. We examined the associations of plasma n-6 and n-3 PUFA in cholesteryl esters with fatal CHD in a
nested case-control study. Additionally, we performed a dose-response meta-analysis of similar prospective studies on
cholesteryl ester PUFA.
Methods: We used data from two population-based cohort studies in Dutch adults aged 20–65y. Blood and data collection
took place from 1987–1997 and subjects were followed for 8–19y. We identified 279 incident cases of fatal CHD and
randomly selected 279 controls, matched on age, gender, and enrollment date. Odds ratios (OR) were calculated per
standard deviation (SD) increase of cholesteryl ester PUFA.
Results: After adjustment for confounders, the OR (95%CI) for fatal CHD per SD increase in plasma linoleic acid was 0.89
(0.74–1.06). Additional adjustment for plasma total cholesterol and systolic blood pressure attenuated this association
(OR:0.95; 95%CI: 0.78–1.15). Arachidonic acid was not associated with fatal CHD (OR per SD:1.11; 95%CI: 0.92–1.35). The ORs
(95%CI) for fatal CHD for an SD increase in n-3 PUFA were 0.92 (0.74–1.15) for alpha-linolenic acid and 1.06 (0.88–1.27) for
EPA-DHA. In the meta-analysis, a 5% higher linoleic acid level was associated with a 9% lower risk (relative risk: 0.91; 95% CI:
0.84–0.98) of CHD. The other fatty acids were not associated with CHD.
Conclusion: In this Dutch population, n-6 and n-3 PUFA in cholesteryl esters were not significantly related to fatal CHD. Our
data, together with findings from previous prospective studies, support that linoleic acid in plasma cholesteryl is inversely
associated with CHD.
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Introduction
Several reviews of prospective cohort studies and randomized
trials suggest that the intake of n-6 and n-3 polyunsaturated fatty
acids (PUFA) protect against coronary heart disease (CHD)
[1,2,3,4]. Linoleic acid, belonging to the n-6 PUFA family, is the
most abundant PUFA in the diet and it is mainly obtained from
vegetable oils, such as sunflower oil and soybean oil [2]. It is an
essential fatty acid that can be elongated to arachidonic acid,
which is also present in meat in small quantities [5,6]. Alpha-
linolenic acid is an essential fatty acid of the n-3 PUFA family and
is present in soybean, canola, and flaxseed oil [2]. Alpha-linolenic
acid can be elongated to eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA). Because these conversions takes
place only to a limited extent (,8%),[7,8,9] EPA and DHA are
mainly derived from the diet, through fish consumption [2].
Biomarkers of dietary intake are widely used in epidemiological
studies [10,11]. They are considered to provide a more accurate
measure of intake than dietary records or questionnaire data,
especially when the nutrient of interest varies widely within foods
and food groups and when food composition tables are inaccurate
for that specific nutrient [12]. Furthermore, biomarkers are not
dependent on a person’s ability to recall dietary intakes. Fatty acids
can be measured as free fatty acids in serum (or plasma), as
components of triglycerides, phospholipids, cholesteryl esters,
erythrocyte membranes, platelets, or in adipose tissue from various
sites [13]. Cholesteryl esters are found in plasma lipoproteins and
reflect dietary intake of PUFA during the previous weeks [14,15].
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Harris et al. [16] performed a meta-analysis of 25 (nested) case-
control studies and prospective cohort studies on tissue fatty acid
composition and risk of CHD published until 2006. Harris et al.
showed that long-chain n-3 PUFA tissue concentrations, especially
DHA, were inversely associated with fatal CHD. However, in their
meta-analysis crude data of PUFA levels were pooled, i.e. potential
confounders were not taken into account. Furthermore, adipose
tissue and various plasma and serum fractions were combined.
We investigated the associations of n-6 and n-3 PUFA,
measured in plasma cholesteryl esters with the risk of fatal CHD
in a prospective case-control study of Dutch adults, adjusted for
confounders. Additionally, we performed a meta-analysis of nested
case-control and cohort studies on plasma PUFA measured in
cholesteryl esters in relation to CHD.
Methods
Ethical Statement
This research was performed in accordance with the ethical
principles for medical research involving human subjects outlined
in the Declaration of Helsinki. This research was approved by the
Academic Hospital Leiden and the Medical Ethics Committees of
TNO Prevention and Health, Leiden, The Netherlands. All
participants gave written informed consent.
Design and study populations
We conducted a nested case-control study using two similar
consecutive Dutch population-based cohorts. The nested case-
control design is considered an efficient alternative to a full-cohort
analysis [17]. Baseline blood samples and information on lifestyle,
and cardiovascular risk factors were collected in 35,475 subjects
aged 20–59 years during 1987–1991 in the Monitoring Project on
Cardiovascular Disease Risk Factors (subsequently referred to as
MP-1) [18,19] and in 22,654 subjects aged 20–65 years during
1993–1997 in the Monitoring Project on Risk Factors for Chronic
Diseases (MORGEN Study; MP-2) [20]. For 7,754 participants
who participated in both cohorts, we used the more recent MP-2
data. In addition, we excluded participants who did not provide
informed consent for vital status follow-up and participants with a
history of myocardial infarction (MI) or stroke at baseline, resulting
in 26,987 participants in MP-1 and 21,335 participants in MP-2.
Vital status was checked through linkage with the national
population register. Participants were followed for cause-specific
mortality through linkage with Statistics Netherlands. Fatal CHD
included fatal MI (I21, I22) and fatal cardiac arrest (CA; I46),
according to the International Classification of Diseases (ICD-10,
WHO). For causes of death coded until January 1, 1996,
corresponding ICD-9 codes were used. Participants were followed
until fatal CHD, death, date of loss-to-follow-up (predominantly
because of emigration) or 1 January 2006, whichever came first.
All cases of fatal MI and fatal CA that occurred during follow-
up (median 12.5 years, range 8–19 years) were identified. For each
case (n = 232 in MP-1 and 69 in MP-2), one control from the same
cohort was selected based on incidence density sampling to reduce
the likelihood of biased results [21,22]. Controls were selected
from those persons under study who survived at least as long as the
index case. A person was eligible to serve as a control for multiple
cases at a given moment in time and could serve both as control
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Figure 1. PRISMA 2009 Flow diagram meta-analysis.
doi:10.1371/journal.pone.0059408.g001
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and case. Cases were individually matched to controls on age (+/
20.5y), gender, and date of entry in the cohort (+/20.5y). Plasma
was available for 222 case-control pairs of MP-1 and 57 pairs of
MP-2 and. In MP-1, five participants were selected as a control
twice and four participants served both as a control and as a case.
In MP-2, 1 participant was selected both as case and control.
Measurement of n-3 PUFA in plasma cholesteryl esters
Participants donated non-fasting blood at baseline. EDTA-
plasma of MP-1 was stored at 230uC and EDTA-plasma of MP-2
was stored at 280uC until analyzed. Fatty acids were measured in
plasma cholesteryl esters by gas chromatography, as described
previously [23]. In short, to isolate cholesteryl esters, lipids from
EDTA plasma were dissolved and separated by solid phase
extraction silica columns (Chrompack, Middelburg, The Nether-
lands). The fatty acids were identified by comparison with known
standards (Nu-chek prep, Inc. Elysian, MN, USA). Fatty acids
were expressed as mass percentages of total fatty acid methyl esters
(g/100 g). A quality control plasma pool was analyzed in duplicate
in each run. Coefficients of variation of the controls (intra and
inter assay combined) ranged between 3 and 3.5 %. Laboratory
technicians were blinded to the status of the samples. Cases and
controls were randomly distributed over the runs.
Data collection on risk factors
The baseline measurements were previously described in detail
by Verschuren et al. [18,20]. Body weight, height, and blood
pressure were measured by trained research nurses. Hypertension
was defined as a systolic blood pressure $140 mmHg, diastolic
blood pressure $90 mmHg, or the use of blood pressure lowering
medication. Non-fasting plasma was analyzed for total and high-
density lipoprotein (HDL) cholesterol, and hypercholesterolemia
was defined as plasma total cholesterol $6.5 mmol/l or use of
cholesterol lowering medication. Self-administered questionnaires
were used to assess the prevalence of diabetes, history of MI or
stroke, medication use, parental history of MI, educational level,
and cigarette smoking. Alcohol intake was calculated in glasses/d
and was categorized as no intake, low to moderate intake (men#2
and women #1 glasses/d), or high intake (men.2 and women .1
glasses/d).
Table 1. Baseline characteristics of 279 fatal coronary heart disease cases and 279 matched controls.*,{
MP-1 MP-2
Cases (n =222) Controls (n =222) P-value` Cases (n =57) Controls (n =57) P-value`
Male gender, % 70 70 – 79 79 –
Age, y 50.567.4 50.567.5 – 51.767.1 51.867.2 –
Body mass index, kg/m2 26.964.7 26.063.9 0.02 27.764.8 26.263.8 0.07
Smoking, %
Never 18 32 – 18 35 –
Former 21 30 – 26 39 –
Current 61 38 ,0.0001 56 26 0.002
Alcohol consumption, %
No intake 38 34 – 23 12 –
Low to moderate 34 36 – 44 67 –
High 27 30 0.29 33 21 0.90
High educational level, % 1 7 14 0.008 21 18 0.82
Parental history of
myocardial infarction, %
9.5 8.7 0.87 5.3 5.3 1.00
Diabetes mellitus, % 5.0 2.7 0.33 5.3 0 0.25
Systolic blood pressure, mm Hg 134.5621.0 125.5615.6 ,0.0001 138.8620.3 126.8617.1 0.001
Diastolic blood pressure, mm Hg 83.4612.4 78.669.7 ,0.0001 85.6612.1 79.769.9 0.002
Blood pressure lowering
medication, %
14.9 9.0 0.06 19.3 10.5 0.23
Hypertension, % 46 28 ,0.0001 56 33 0.002
Plasma total cholesterol, mmol/l || 6.561.3 5.961.1 ,0.0001 5.861.0 5.761.0 0.83
Plasma HDL-cholesterol, mmol/l || 1.160.3 1.260.3 0.002 1.2 60.4 1.360.3 0.15
Cholesterol lowering
medication, %
1.8 0.5 0.25 1.8 0 1.00
Hypercholesterolemia, % 42 27 0.001 26 19 0.42
Footnotes to Table 1.
*Values are means 6 SD, unless indicated otherwise.
{Controls were matched on age, gender, cohort, and enrollment date.
`Paired t-test for linear values and Wilcoxon signed-rank test for proportions.
1Completed higher vocational training or university.
|| Non-fasting.
doi:10.1371/journal.pone.0059408.t001
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Statistical analysis
In descriptive analyses, we compared the prevalence of risk
factors and mean levels (6SD) of plasma fatty acids between cases
and controls, stratified for cohort. The significance of differences
in crude means or frequencies of risk factors were assessed by
paired t-test for continuous variables and by the Wilcoxon signed-
rank test for categorical variables. We used conditional logistic
regression models to calculate odds ratios (OR) with 95%
confidence intervals (95% CI) for the association of plasma levels
of linoleic acid, arachidonic acid, alpha-linolenic acid, EPA, DHA,
and EPA-DHA with fatal CHD. The analyses were repeated
within the two separate cohorts. ORs and 95% CI for fatal CHD
were calculated per SD increase in the plasma fatty acids, based on
the distribution of controls.
In model 1, we adjusted for the matching factors age, gender,
cohort, and enrollment date. In model 2, we additionally adjusted
for current cigarette smoking (yes/no), body mass index (kg/m2),
alcohol intake (no, low to moderate, or high), high educational
level (completed higher vocational training or university). In model
3 we also adjusted for systolic blood pressure (mmHg) and plasma
total cholesterol (mmol/l). Two-sided p-values ,0.05 were
considered to be statistically significant. Descriptive statistics and
logistic regression analyses were performed with Statistical
Analysis Software (SAS), version 9.2.
We performed a dose response meta-analysis of all available
published (searched with Pubmed) prospective studies (cohort
studies or nested case-control studies) that measured cholesteryl
ester PUFA status in relation to CHD risk including the estimates
of the two separate cohorts of the current study. We identified five
publications with relative risks on cholesteryl ester PUFA in
relation to fatal and nonfatal CHD [24,25,26,27,28], of which one
could not be used due to missing data on fatty acid levels [26]
(Figure 1). In the original publication of Warensjo¨ et al [28], the
endpoint was fatal CVD. Data on CHD were kindly provided by
the authors upon request. We used STATA version 11.0 (STAT
Corp, College Station, TX) for meta-analyses using the METAN
command. The generalized least-squares method for trend
estimation of summarized dose-response data was used to calculate
a relative risk for a certain unit of the exposure based on the
Greenland and Longnecker method [29]. Each study was
weighted by the inverse of its variance, including both the within
and between study variance. Between-study heterogeneity was
assessed via the I2 statistic, which expresses the percentage of
variation attributable to between-study heterogeneity [30]. Ran-
dom effects pooling were conducted according to DerSimonian
and Laird [31]. We visualized and summarized the associations
between different PUFA and CHD outcomes in forest plots.
Results
Nested cases-control study of plasma cholesteryl fatty
acids and fatal CHD
Cases comprised 235 fatal MI (187 from MP-1 and 48 from
MP-2) and 44 cardiac arrest events (35 from MP-1 and 9 from
MP-2). Cases and matched controls from MP-2 were on average
around 51 years old and 79% was male. Compared to MP-2, cases
and controls from MP-1 had a similar age, but consisted of fewer
males (70%). In both cohorts, cases had a higher body mass index,
smoked more, more often used anti-hypertensive medication, and
had higher blood pressure levels than controls. Cases of MP-1 also
had higher plasma total cholesterol levels compared to controls
(Table 1).
Table 2 shows fatty acid levels for CHD cases and matched
controls. The levels of linoleic acid, arachidonic acid, alpha-
linolenic acid, and EPA-DHA were all lower in MP-1 as compared
to MP-2. Linoleic acid values were (non-significantly) lower in
cases compared to controls, although this was not statistically
significant. The other fatty acid levels did not differ between cases
and controls.
Cases and controls did not differ statistically in plasma n-6 and
n-3 PUFA (Table 3). In the crude model, linoleic acid status was
borderline significantly inversely associated with fatal CHD with
Table 2. Fatty acid proportions in plasma cholesteryl esters in 279 Dutch fatal CHD cases and 279 matched controls.*,{
Fatty acids (g/100 g) ` Cases Controls P-value 1
MP-1 N= 222 N= 222
Linoleic acid C18:2n-6 42.967.0 43.866.3 0.15
Arachidonic acid C20:4n-6 3.861.1 3.961.2 0.54
Alpha-linolenic acid C18:3n-3 0.3960.13 0.3860.14 0.56
EPA C20:5n-3 0.5960.45 0.5960.42 0.73
DHA C22:6n-3 0.3360.16 0.3360.15 0.59
EPA-DHA C20:5n-3+C22:6n-3 0.9260.57 0.9160.54 0.996
MP-2 N= 57 N=57
Linoleic acid C18:2n-6 52.965.3 54.464.8 0.14
Arachidonic acid C20:4n-6 6.861.6 6.461.6 0.18
Alpha-linolenic acid C18:3n-3 0.5160.15 0.5160.14 0.95
EPA C20v5n-3 0.9360.64 0.8960.57 0.88
DHA C22:6n-3 0.5460.22 0.5260.22 0.46
EPA-DHA C20:5n-3+C22:6n-3 1.4860.82 1.4160.74 0.69
*Fatty acid levels are expressed as mass percentages (g/100 g).
{Controls were matched on age, gender, cohort, and enrollment date.
`Fatty acid levels are expressed as means 6 SD.
1Paired t-test, log transformed values were used for EPA, DHA, and EPA+DHA.
doi:10.1371/journal.pone.0059408.t002
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Table 3. Associations between plasma cholesteryl ester fatty acids and fatal CHD, matched by age, gender, cohort, and enrollment
date.*
Model 1 { Model 2 ` Model 3 1
OR (95% CI) OR (95% CI) OR (95% CI)
Combined cohorts N=558
Linoleic acid 0.86 (0.74–1.00) 0.89 (0.74–1.06) 0.95 (0.78–1.15)
Arachidonic acid 1.00 (0.85–1.18) 1.06 (0.88–1.27) 1.11 (0.92–1.35)
Alpha-linolenic acid 1.05 (0.87–1.25) 0.97 (0.79–1.19) 0.92 (0.74–1.15)
EPA 1.02 (0.88–1.20) 1.07 (0.90–1.26) 1.04 (0.86–1.24)
DHA 1.02 (0.87–1.20) 1.09 (0.91–1.31) 1.12 (0.92–1.36)
EPA+DHA 1.03 (0.88–1.20) 1.08 (0.91–1.27) 1.06 (0.88–1.27)
MP-1 N=444
Linoleic acid 0.88 (0.75–1.05) 0.90 (0.74–1.10) 0.97 (0.78–1.21)
Arachidonic acid 0.95 (0.79–1.13) 1.02 (0.83–1.25) 1.08 (0.87–1.34)
Alpha-linolenic acid 1.06 (0.87–1.31) 1.01 (0.80–1.26) 0.93 (0.72–1.19)
EPA 1.01 (0.85–1.21) 1.06 (0.87–1.28) 1.02 (0.83–1.25)
DHA 1.00 (0.84–1.20) 1.07 (0.88–1.30) 1.11 (0.89–1.37)
EPA+DHA 1.01 (0.85–1.20) 1.06 (0.88–1.29) 1.04 (0.85–1.28)
MP-2 N=114
Linoleic acid 0.77 (0.54–1.10) 0.80 (0.53–1.23) 0.83 (0.53–1.32)
Arachidonic acid 1.32 (0.88–1.96) 1.26 (0.79–2.03) 1.29 (0.78–2.12)
Alpha-linolenic acid 0.99 (0.68–1.45) 0.87 (0.56–1.37) 1.01 (0.61–1.70)
EPA 1.08 (0.76–1.51) 1.11 (0.72–1.70) 1.06 (0.65–1.74)
DHA 1.15 (0.77–1.71) 1.22 (0.72–2.05) 1.15 (0.65–2.05)
EPA+DHA 1.09 (0.77–1.55) 1.13 (0.73–1.77) 1.08 (0.65–1.80)
EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid.
*Values are odds ratios (95% CI) per standard deviation increase, based on conditional logistic models.
{Crude model, matched for age, gender, cohort, and enrollment date.
`Additional adjustment for smoking, BMI, education level, alcohol intake.
1Additional adjustment for systolic blood pressure, total cholesterol.
doi:10.1371/journal.pone.0059408.t003
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an OR of 0.86 (95% CI: 0.74–1.00). In model 2, the OR (95% CI)
for fatal CHD per SD increase in linoleic acid was 0.89 (0.74–
1.06). Additional adjustment for plasma total cholesterol and
systolic blood pressure (model 3) further attenuated the estimate.
Plasma arachidonic acid was not associated with fatal CHD. The
ORs (95% CI) for fatal CHD for an SD increase in n-3 PUFA
were 0.92 (0.74–1.15) for plasma alpha-linolenic acid and 1.06
(0.88–1.27) for plasma EPA-DHA.
Meta-analysis of prospective studies on cholesteryl ester
PUFA in relation to CHD
For the meta-analysis, we pooled the current data with results of
two nested case-control studies from the USA[24,25] and two
cohort studies from Finland and Sweden on cholesteryl ester
PUFA in relation to fatal and nonfatal CHD [27,28]. The mean
baseline age ranged from 50–60 years and the mean follow-up
time ranged from 5–34 years between studies. Three studies
comprised only men [24,25,28] and the other included men and
women. For MP-1 and MP-2 we used the estimates of model 3, as
that model was most comparable to the data of the other included
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studies. After pooling all studies, a 5% higher linoleic acid level
was associated with a 9% lower risk (relative risk: 0.91; 95% CI:
0.84–0.98) of CHD. The other fatty acids were not associated with
CHD. For DHA status we observed significant heterogeneity
(p,0.001) (Figure 2–6). Exclusion of the study of Erkkila¨ et al.,
which was the only study with coronary patients, resulted in a
pooled OR (95% CI) of 1.09 (0.95–1.11) without heterogeneity
(p = 0.49).
Discussion
In a nested case-control study in Dutch adults we did not
observe statistically significant associations between plasma
cholesteryl ester linoleic acid levels and fatal CHD. When we
pooled these data with those from similar prospective studies in a
meta-analysis, a 5% higher linoleic acid level was related to a
significant 9% lower CHD risk. Arachidonic acid and the n-3
PUFA alpha-linolenic acid, EPA, and DHA were not associated
with CHD risk in the present study and in the meta-analysis.
A limitation of our study could be that the blood samples were
stored for 18–23 years for MP-1 and 12–17 years for MP-2, which
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may have affected the quality of plasma fatty acids. However,
storage up to 10 years at 280uC did not significantly influence
serum cholesteryl ester fatty acid profiles in a recent validation
study [32]. Although the n-6 and n-3 PUFA levels of the (older)
MP-1 samples were considerably lower than those of the MP-2
samples, we do not expect that the values were differentially lower
for cases compared to controls. The number of detected fatty acids
(15–20) and the percentage of unknown fractions (rule of thumb
,5%) were as expected for both cohorts. Furthermore, potential
measurement error will have been random because the plasma
samples of cases and controls were identically handled and
analyzed in random order, and lab technicians were blinded for
disease outcome. A strength of the present analysis was that we
used two similar, large population-based cohort studies, with
almost complete mortality follow-up.
The present nested case-control study did not show a statistically
significant association between plasma cholesteryl ester linoleic
acid levels and fatal CHD. However, a 5% higher linoleic acid
level was related to a significant 9% lower CHD risk (OR: 0.91;
95% 0.84–0.98) in a meta-analysis in which we combined our
findings with data from similar prospective studies. In the meta-
analysis of Harris et al. [16], linoleic acid was not associated with
CHD risk, based on a pooled estimate of seven prospective studies
with various blood fractions. Plasma arachidonic acid did not
predict CHD in our nested case-control study and meta-analysis,
which was in agreement with Harris et al. [16]. In our nested case-
control study and meta-analysis, we observed no association of
cholesteryl ester alpha-linolenic acid or EPA-DHA with CHD,
whereas Harris et al. [16] observed a borderline significantly lower
alpha-linolenic acid status in CHD cases. Furthermore, DHA, but
not EPA, was significantly inversely associated with CHD in the
subgroup of prospective studies in the meta-analysis of Harris et al.
[16].
The current meta-analysis and the one of Harris et al. [16] show
different results, mainly for linoleic acid and DHA. Some
differences in design could be responsible for this. Although
Harris et al. combined data of a large number of studies, 16 out of
the 25 studies had a classical case-control design (based on
prevalent cases), which is more prone to reverse-causation and
selection bias. Seven studies (case-control studies only) were based
on adipose tissue samples. The other 18 used various blood
fractions, such as phospholipids, cholesteryl esters, and erythro-
cytes, which could cause substantial heterogeneity in meta-analysis
results. Finally, the analysis was based on crude PUFA levels.
Potential confounding e.g. by body mass index and smoking,
which appeared to be strong confounders in the present analysis,
may partly explain discrepant results between the two meta-
analyses.
Linoleic acid is by far the most important fatty acid in
cholesteryl esters, followed by oleic acid, palmitic acid, and
arachidonic acid [33]. In contrast, the concentrations of n-3 PUFA
are very low. Therefore, in the n-3 PUFA, the variation between
persons was probably small compared to the within-person
variation. An American validation study reported that short and
long-term reliability coefficients i.e. the ratio of between-person
variance to total variance were .0.7 for cholesteryl ester linoleic
acid, whereas these coefficients ranged between 0.4–0.5 for fatty
acids that composed,1% of total cholesteryl ester fatty acids. The
variance of the method was only,5% of the total variance [34]. A
low between to within-person variation ratio will hamper finding
significant associations between these fatty acids and fatal CHD.
This is probably the reason why the associations between these
PUFA and fatal CHD are inconsistent.
In conclusion, our findings in combination with those from
other prospective studies support an inverse association between
linoleic acid in plasma cholesteryl esters and CHD risk. For plasma
cholesteryl ester levels of n-3 PUFA, however, no relations with
CHD risk were found in our prospective study and meta-analysis,
which raises concern regarding the validity of these biomarkers of
intake for epidemiological studies.
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